Prices as of 2026/10/30 close
Company comparison · Major Pharmaceuticals
Takeda is the largest by revenue at ¥4.5T, followed by Astellas (¥2.1T), Daiichi Sankyo (¥2.1T) and Sumitomo Pharma (¥453.3B).
Sumitomo Pharma has the highest operating margin at 23.7%, 14.6 points above the lowest, Takeda (9.1%).
Revenue growth in the latest results: Sumitomo Pharma +13.7%, Daiichi Sankyo +12.6%, Astellas +11.9%, Takeda −1.7%. For next year, Daiichi Sankyo guides for the fastest operating profit growth (+37.5%).
Takeda pays the most on average (¥11.0M), ¥1.98M more than Sumitomo Pharma (¥9.06M).
Over the past year the shares moved Astellas +63.2%, Takeda +57.1%, Sumitomo Pharma +13.9%, Daiichi Sankyo −28.7%.
Head-to-head wins16 metrics
One win per metric for the company with the best value. Metrics with no better or worse (P/E, average age, employees) are excluded.
ScaleInvestors
Takeda aheadTakeda 2 : Astellas 1 : Daiichi Sankyo 0 : Sumitomo Pharma 0
Revenue: Takeda ¥4.5T / Astellas ¥2.1T / Daiichi Sankyo ¥2.1T / Sumitomo Pharma ¥453.3B
ProfitabilityInvestors
Sumitomo Pharma aheadTakeda 1 : Astellas 0 : Daiichi Sankyo 0 : Sumitomo Pharma 2
Operating margin: Takeda 9.1% / Astellas 17.9% / Daiichi Sankyo 10.8% / Sumitomo Pharma 23.7%
GrowthInvestors
EvenTakeda 0 : Astellas 1 : Daiichi Sankyo 2 : Sumitomo Pharma 2
Revenue growth (YoY): Takeda −1.7% / Astellas +11.9% / Daiichi Sankyo +12.6% / Sumitomo Pharma +13.7%
Stock & balance sheetInvestors
EvenTakeda 0 : Astellas 1 : Daiichi Sankyo 0 : Sumitomo Pharma 1
Share price, 1 year: Takeda +57.1% / Astellas +63.2% / Daiichi Sankyo −28.7% / Sumitomo Pharma +13.9%
Pay & workforceJob seekers
Daiichi Sankyo aheadTakeda 1 : Astellas 0 : Daiichi Sankyo 2 : Sumitomo Pharma 0
Average salary: Takeda ¥11.0M / Astellas ¥10.5M / Daiichi Sankyo ¥11.0M / Sumitomo Pharma ¥9.06M
| Metric | Takeda | Astellas | Daiichi Sankyo | Sumitomo Pharma |
|---|---|---|---|---|
| Revenue | ◎¥4.5T | ¥2.1T | ¥2.1T | ¥453.3B |
| Operating profit | ◎¥408.8B | ¥382.6B | ¥229.1B | ¥107.3B |
| Net income | ¥191.8B | ◎¥291.5B | ¥259.9B | ¥106.9B |
| Metric | Takeda | Astellas | Daiichi Sankyo | Sumitomo Pharma |
|---|---|---|---|---|
| Operating margin | 9.1% | 17.9% | 10.8% | ◎23.7% |
| Net margin | 4.3% | 13.6% | 12.2% | ◎23.6% |
| Revenue per employee | ◎¥937M | ¥521M | ¥265M | ¥259M |
| Metric | Takeda | Astellas | Daiichi Sankyo | Sumitomo Pharma |
|---|---|---|---|---|
| Revenue growth (YoY) | −1.7% | +11.9% | +12.6% | ◎+13.7% |
| Operating profit growth (YoY) | +19.3% | ◎+832.4% | −31.0% | +272.6% |
| Revenue CAGRlast 5 years | +7.1% | +11.4% | ◎+17.1% | −2.6% |
| Guidance: revenue growthnext FY plan | +3.0% | +3.8% | +7.4% | ◎+19.1% |
| Guidance: op. profit growthnext FY plan | +2.7% | +3.2% | ◎+37.5% | −16.2% |
| Metric | Takeda | Astellas | Daiichi Sankyo | Sumitomo Pharma |
|---|---|---|---|---|
| Share price, 1 year | +57.1% | ◎+63.2% | −28.7% | +13.9% |
| Share price, 3 months | +16.3% | +12.4% | −4.7% | ◎+46.0% |
| Share price (close) | ¥6,651 | ¥2,571 | ¥2,754 | ¥1,884.5 |
◎ marks the best value for each metric. Revenue and profit are from the latest full-year earnings release; share prices are closing-price references; P/E = latest close ÷ trailing EPS. For banks and some other financials, revenue means ordinary income.
| Metric | Takeda | Astellas | Daiichi Sankyo | Sumitomo Pharma |
|---|---|---|---|---|
| Average salary | ◎¥11.0M | ¥10.5M | ¥11.0M | ¥9.06M |
| Starting salary (monthly) | ¥300,000 | ¥326,700 | ◎¥360,500 | ¥245,000 |
| Average tenure | 14.4 yrs | 15.7 yrs | ◎19.9 yrs | 18.9 yrs |
| Average age | 43.4 | 42.3 | 45.0 | 44.5 |
| Employees | 4,808 | 4,105 | 8,009 | 1,747 |
Average salary is for the reporting (parent) company and is affected by average age and job mix. Holding companies with few employees are left out of the salary comparison.
Close (Oct 30, 2026)
¥6,651+57.1% (1Y)
Takeda +57.1% over 1Y. Compared: Astellas +63.2%, Daiichi Sankyo -28.7%, Sumitomo Pharma +13.9%.
Reference chart of daily closing prices, not real-time quotes (split-adjusted; weekly closes before the last year). Each line shows the % change from the start of the period. Updated Oct 30, 2026.
Takeda5 segments
Astellas3 segments
Daiichi Sankyo3 segments
Sumitomo Pharma3 segments
AAverage annual salary from the securities filings: Takeda ¥11.0M, Daiichi Sankyo ¥11.0M, Astellas ¥10.5M, Sumitomo Pharma ¥9.06M. Takeda pays the most. Averages also depend on staff age and job mix, so check the average age too (Takeda 43.4, Astellas 42.3, Daiichi Sankyo 45.0, Sumitomo Pharma 44.5).
ARevenue in the latest results: Takeda ¥4.5T, Astellas ¥2.1T, Daiichi Sankyo ¥2.1T, Sumitomo Pharma ¥453.3B. Takeda is the largest by revenue at ¥4.5T, followed by Astellas (¥2.1T), Daiichi Sankyo (¥2.1T) and Sumitomo Pharma (¥453.3B).
AOperating margins: Sumitomo Pharma 23.7%, Astellas 17.9%, Daiichi Sankyo 10.8%, Takeda 9.1%. Sumitomo Pharma turns the highest share of sales into operating profit.
AShare price change over the past year (closing prices, for reference): Astellas +63.2%, Takeda +57.1%, Sumitomo Pharma +13.9%, Daiichi Sankyo −28.7%. Astellas has risen the most.
Comparing 4 companies (up to 4)
Sources: earnings releases (kessan tanshin), annual securities reports and other public information. Share prices are closing-price references, not real-time. Our data may contain errors; investment decisions are your own responsibility.
